Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

4.9K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.9K
Bone Disorders01:29

Bone Disorders

3.8K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.8K
Growth of Cartilage and Bone Tissue01:27

Growth of Cartilage and Bone Tissue

3.4K
Chondrocytes form a temporary cartilaginous model by dividing and secreting a thick gel-like extracellular matrix. Once the chondrocytes undergo programmed cell death, osteoblasts enter the site of the cartilaginous model. The process of replacing the temporary cartilaginous model with bone in an ordered manner is called endochondral ossification. In endochondral ossification, not all of the cartilage is replaced by bone tissue. Some cartilage that performs a protective and supportive function...
3.4K
Fractures: Bone Repair01:27

Fractures: Bone Repair

3.5K
Treatment for a fracture is based on the type of break, the bone affected, and the patient's age.
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
3.5K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.0K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.0K
Bone Formation by Endochondral Ossification01:24

Bone Formation by Endochondral Ossification

5.0K
Bone formation, or ossification, begins around the sixth to seventh week of embryonic development. Most bones develop from a cartilaginous template through the process of endochondral ossification. Cartilage formation begins when clusters of mesenchymal cells differentiate into chondrocytes. These chondrocytes proliferate rapidly and secrete an extracellular matrix that becomes encased in a membrane called the perichondrium. The resulting cartilage model provides a template that resembles the...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Release of microplastics and metals from antifouling paint during weathering in simulated cold climates.

Environmental science. Processes & impacts·2026
Same author

A cell-nonautonomous heme acquisition pathway enables erythroid hemoglobinization under stress.

Science (New York, N.Y.)·2026
Same author

Dual-transformed CuO nanoparticles modulate plant nutrition and stress physiology in copper-starved plants.

Environmental pollution (Barking, Essex : 1987)·2026
Same author

A cell-nonautonomous heme acquisition pathway enables erythroid hemoglobinization under stress.

bioRxiv : the preprint server for biology·2026
Same author

Sclerostin deficiency sensitizes white adipocytes to thermogenic signals that induce beiging in mice.

Nature communications·2026
Same author

Senescent Cells Involved in Deterioration of Bone Microstructure by High-Frequency Parathyroid Hormone 1-34 Administration and Bone Loss.

Aging cell·2025

Related Experiment Video

Updated: Aug 21, 2025

Labeling of Extracellular Vesicles for Monitoring Migration and Uptake in Cartilage Explants
07:58

Labeling of Extracellular Vesicles for Monitoring Migration and Uptake in Cartilage Explants

Published on: October 4, 2021

2.7K

MSC-EV therapy for bone/cartilage diseases.

Joe Kodama1, Kevin J Wilkinson1, Satoru Otsuru1

  • 1Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, MD, USA.

Bone Reports
|November 17, 2022
PubMed
Summary
This summary is machine-generated.

Mesenchymal stromal cell (MSC)-derived extracellular vesicles (EVs) show therapeutic promise, but batch-to-batch variability in EV quality hinders clinical use. Standardizing EV production is crucial for consistent cell therapy outcomes in bone and cartilage diseases.

Keywords:
Extracellular vesicles (EVs)MSC-EV therapyMesenchymal stromal cells (MSCs)OsteoarthritisOsteoporosisRheumatoid arthritis

More Related Videos

Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture
09:48

Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture

Published on: July 26, 2022

4.5K
Author Spotlight: Enhancing Bone Regeneration with Vascularized Artificial Cartilage Integration
06:05

Author Spotlight: Enhancing Bone Regeneration with Vascularized Artificial Cartilage Integration

Published on: July 14, 2023

1.1K

Related Experiment Videos

Last Updated: Aug 21, 2025

Labeling of Extracellular Vesicles for Monitoring Migration and Uptake in Cartilage Explants
07:58

Labeling of Extracellular Vesicles for Monitoring Migration and Uptake in Cartilage Explants

Published on: October 4, 2021

2.7K
Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture
09:48

Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture

Published on: July 26, 2022

4.5K
Author Spotlight: Enhancing Bone Regeneration with Vascularized Artificial Cartilage Integration
06:05

Author Spotlight: Enhancing Bone Regeneration with Vascularized Artificial Cartilage Integration

Published on: July 14, 2023

1.1K

Area of Science:

  • Cellular and Molecular Biology
  • Regenerative Medicine
  • Biotechnology

Background:

  • Mesenchymal stromal cells (MSCs) are used in cell therapy.
  • Extracellular vesicles (EVs) from MSCs mediate therapeutic effects by transferring bioactive molecules.
  • EV therapy offers potential but faces challenges in quality control and standardization.

Purpose of the Study:

  • To discuss factors influencing MSC-derived EV quality.
  • To review preclinical studies on EV therapy for bone and cartilage diseases.
  • To highlight the need for scalable, consistent EV manufacturing for clinical translation.

Main Methods:

  • Literature review of MSC-derived EV research.
  • Analysis of factors affecting EV production and quality.
  • Summary of preclinical findings in osteoarthritis, rheumatoid arthritis, and osteoporosis models.

Main Results:

  • EVs contain proteins, mRNAs, and miRNAs that modulate recipient cell function.
  • Significant variability in EV quality exists between different preparations.
  • Preclinical data suggest therapeutic potential for EVs in bone and cartilage regeneration.

Conclusions:

  • Standardized, scalable manufacturing of high-quality EVs is essential for clinical success.
  • Addressing EV quality control is critical for reproducible therapeutic outcomes.
  • EV therapy holds promise for treating degenerative bone and joint conditions.